Mekinist (trametinib tablets and oral solution – Novartis) — Cigna

Initial criteria

• Patient has recurrent, advanced, or metastatic disease; AND
• Patient has BRAF V600 mutation-positive disease; AND
• The medication is prescribed in combination with Tafinlar (dabrafenib capsules or tablets for oral suspension).

Approval duration

1 year